Organogenesis Holdings Inc (FRA:2PQ)
€ 2.9 -0.12 (-3.97%) Market Cap: 383.32 Mil Enterprise Value: 396.10 Mil PE Ratio: 0 PB Ratio: 1.51 GF Score: 74/100

Organogenesis Holdings Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript

Sep 20, 2021 / 07:45PM GMT
Release Date Price: €13.2 (-5.04%)
Steve Lichtman
Oppenheimer & Co. Inc. - Analyst

Hi, everyone. I am Steve Lichtman, medical devices analyst at Oppenheimer. Welcome back to the Fall Oppenheimer Healthcare Summit. We're very happy to have with us up next, Organogenesis Holdings, a leader in the advanced wound care market. With us today are Gary Gilheeney, Chief Executive Officer; and Dave Francisco, Chief Financial Officer. Gary and Dave will be going through the presentation today. If we have some time at the end, we will go through some Q&A. But with that, I'm going to turn the podium over to Gary and Dave. Thanks for joining us.

Gary Gilheeney
Organogenesis Holdings Inc. - Director, President & CEO

Thanks, Steve. Appreciate the opportunity to talk about Organogenesis, kind of where we have been and where we are heading. So just to give you a sense of the Company's evolution, we have been around a long time. The Company was actually formed in 1985 based on technology out of MIT, Dr. Eugene Bell's lab, and did primary research all the way to 1998 when we launched the product,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot